Potential Utility of Sodium Selenate as an Adjunct to Metformin in Treating Type II Diabetes Mellitus in Rats: A Perspective on Protein Tyrosine Phosphatase

Figure 2

Changes in the glucose area under the curve (AUC) as derived from the OGTT for normal control, nontreated DIR and treated rats by metformin, sodium selenate and their combination at 𝑃<0.05, 𝑃<0.01, and 𝑃<0.001. Values represent the mean of 6 rats ± SEM (one-way ANOVA followed by LSD test). DIR: diabetic/insulin resistant, DIR + Met: diabetic/insulin resistant + metformin, DIR + Sel: diabetic/insulin resistant + sodium selenate, DIR + Met + Sel: diabetic/insulin resistant + metformin + sodium selenite. ^(c)𝑃<0.001 compared to control group. ^(f)𝑃<0.001 compared to DIR group.